21
Participants
Start Date
September 30, 2014
Primary Completion Date
June 30, 2016
Study Completion Date
June 30, 2016
Sativex
Administered orally as a spray to the cheek according to a standard dose titration regimen, until patients reach a maximum tolerated dose (maximum 12 sprays per day). Each spray delivers 100 μl (Δ9tetrahydrocannabinol (THC), 27 mg/ml: Cannabidiol (CBD), 25 mg/ml).
Placebo
Administered orally as a spray to the cheek according to a standard dose titration regimen, until patients reach a maximum tolerated dose (maximum 12 sprays per day). Each spray delivers 100 μl ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring and Food, Drugs \& Cosmetics (FD\&C)certified color additives; FD\&C Yellow No.5 (E102 tartrazine) (0.0260%), FD\&C Yellow No.6 (E110 sunset yellow) (0.0038%), FD\&C Red No. 40 (E129 Allura red AC) (0.00330%) and FD\&C Blue No.1 (E133 Brilliant blue FCF) (0.00058%).
Zentrum für Neuroonkologie der Universität Duesseldorf, Düsseldorf
Klinik für Onkologie, Hämatologie und Stammzelltransplantation, Universitätsklinikum Aachen RWTH, Aachen
Strahlenklinik der Universität Erlangen, Erlangen
Neurologie des Klinikums Altenburger Land, Altenburg
The Clatterbridge Cancer Centre NHS Foundation Trust, Bebington
St James's Institute of Oncology, St James's University Hospital, Leeds
Bristol Haematology & Oncology Centre, Bristol
Queen's Centre for Haematology & Oncology, Castle Hill Hospital, Cottingham
West of Scotland Beatson Cancer Centre, Glasgow
Guy's & St Thomas' NHS Foundation Trust, of St Thomas' Hospital, London
The Christie NHS Foundation Trust, Manchester
Lead Sponsor
Jazz Pharmaceuticals
INDUSTRY